If you had read the headlines about this infant formula business it would be easy to anticipate the stock trading higher after it gained US FDA approval in late 2021 plus revenue from China already appears to have turned but the stocks halved over the last few months i.e. a lack of guidance from the company back in August following their result clearly hasn’t helped.
- We need a positive catalyst before MM will consider BUB as an investment.
MM is neutral BUB ~30c
Add To Hit List
